Investigation Into Genetic Factors in Drug Side Effects

A recent study involving the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England aims to explore whether genetic variations affect the likelihood of developing acute pancreatitis after using GLP-1 receptor agonist medications—like Ozempic, Mounjaro, and Wegovy—intended for weight loss and the management of Type 2 diabetes.

Sky News reports that the MHRA has received a total of 181 cases linking acute or chronic pancreatitis to the weight-loss drug Mounjaro, including five fatalities.

Additionally, other GLP-1 medications, specifically Wegovy and Ozempic, have been connected to 113 pancreatitis reports and one death, according to the outlet.

There have also been mentions of lesser-known GLP-1 drugs being associated with similar pancreatitis cases and additional deaths.

Genetic Link to Drug Side Effects

The Yellow Card Biobank, which is groundbreaking in its approach, will gather genetic information from patients hospitalized with acute pancreatitis that may be related to GLP-1 medications. These drugs, often referred to as “skinny jabs,” simulate natural hormones that help control appetite and blood sugar levels. While not common, acute pancreatitis can be a serious condition reported by users.

Dr. Alison Cave, the Chief Safety Officer for the MHRA, remarked, “This is about preventing side effects before they happen.” She noted that nearly a third of side effects might be avoidable with genetic screenings, calling this study a significant move towards personalized medicine.

How It Works

Patients who have been hospitalized with acute pancreatitis while on GLP-1 medications are encouraged to share their experiences through the Yellow Card scheme. Healthcare providers are also urged to report any suspected cases and to refer patients accordingly.

When a Yellow Card is submitted, the MHRA will reach out to eligible participants for the Biobank study. These individuals will then be asked to send a saliva sample—which will be collected through the mail—helping to identify genetic markers that could elevate the risk of pancreatitis. Researchers will analyze these samples to determine whether specific genetic traits are linked to side effects.

Understanding GLP-1 Medicines (“Skinny Jabs”)

So, what are GLP-1 receptor agonists? Drugs such as Ozempic, Wegovy, Mounjaro, and Rybelsus assist in regulating appetite and blood sugar by mimicking a natural hormone. Interestingly, some of these, like Mounjaro, act on an additional hormone as well.

In the UK, these medications are approved solely for individuals dealing with obesity or Type 2 diabetes. Their use for aesthetic weight loss purposes hasn’t received official approval.

It’s essential that these medications are prescribed by a qualified healthcare provider after an appropriate consultation. They are accessible through the NHS in specific situations or via private clinics.

Buying these drugs from unregulated sources, like beauty salons or social media, is highly discouraged. Unauthorized or counterfeit GLP-1 products can lead to severe side effects, so it’s crucial to trust only licensed pharmacies with prescriptions.